A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies

syahrir maulana Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is a late-stage biopharmaceutical company focused on developing radiotherapies for Acute Myeloid Leukemia [AML] patients who have not responded to standard treatments. The firm's leading product candidates are Iomab-B and Actimab-A, which use radiation targeted to leukemia-related antigens to kill cancer without affecting healthy cells, presenting an enhanced treatment efficacy with fewer adverse effects. Iomab-B demonstrated promising phase 3 resul ...